CIBC Asset Management
RARE icon

CIBC Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

CIBC Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,908
Closed -$211K – 1435
2022
Q1 		$211K Hold
2,908
– – ﹤0.01% 1345
2021
Q4 		$245K Buy
2,908
+164
+6% +$13.3K ﹤0.01% 1221
2021
Q3 		$247K Buy
2,744
+295
+12% +$26.7K ﹤0.01% 1165
2021
Q2 		$234K Hold
2,449
– – ﹤0.01% 1172
2021
Q1 		$279K Buy
2,449
+195
+9% +$26.5K ﹤0.01% 1001
2020
Q4 		$312K Buy
+2,254
New +$267K ﹤0.01% 886

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

CIBC Asset Management's RARE Position: Q2 2022 in Review

CIBC Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 2,908 shares — an estimated $211K sold.

CIBC Asset Management first reported a position in RARE in Q4 2020 and held it in 6 quarters. The position peaked at $312K in Q4 2020. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

  • CIBC Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • CIBC Asset Management sold 2,908 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $211K.
  • CIBC Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 6 quarters.
  • CIBC Asset Management's Ultragenyx Pharmaceutical position peaked at $312K in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.